Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2
被引:1
作者:
Burris, HA
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Burris, HA
Hainesworth, JD
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Hainesworth, JD
Albain, K
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Albain, K
Huntington, M
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Huntington, M
Greco, FA
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Greco, FA
Erland, J
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Erland, J
Hussain, A
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Hussain, A
Vogel, CL
论文数: 0引用数: 0
h-index: 0
机构:Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
Vogel, CL
机构:
[1] Sarah Cannon Canc Ctr, Drug Dev, Nashville, TN USA
[2] Loyola Univ, Chicago, IL 60611 USA
[3] Teton Med Ctr, Idaho Falls, ID USA
[4] Columbia Canc Res Network Florida, Aventura, FL USA